NCT03856099

TTAC-0001 Phase II Trial With Recurrent Glioblastoma Progressed on Bevacizumab

A Multicenter, Open-Label, Phase Ⅱ Clinical Trial to Evaluate the Safety and Efficacy of TTAC-0001, a Fully Human Monoclonal Antibody in Patients With Recurrent Glioblastoma Progressed on Bevacizumab Including Therapy

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 19 (actual)
• Sponsor: PharmAbcine · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a phase II, open-Label clinical trial to evaluate the safety and efficacy of TTAC-0001 in patients with recurrent glioblastoma who was progressed on bevacizumab including therapy.

Conditions

• Recurrent Glioblastoma

Interventions

Type	Name	Description
DRUG	TTAC-0001	* Investigational product (IP): TTAC-0001 * Treatment groups: 3 dose groups * Dose group A : TTAC-0001 16 mg/kg on D1 and D15 * Dose group B : TTAC-0001 20 mg/kg on D1 and D15 * Dose group C : TTAC-0001 24 mg/kg on D1 and D15 * Cycle: 4 weeks (28 days per cycle)

Timeline

• Start date: 2019-11-13
• Primary completion: 2022-07-15
• Completion: 2022-07-15
• First posted: 2019-02-27
• Last updated: 2022-08-18

Locations

3 sites across 2 countries: United States, Australia

Regulatory

• FDA-regulated drug study